When IL-17 inhibitors fail: real-life evidence to switch from secukinumab to adalimumab or ustekinumab

Giovanni Damiani, Rosalynn Rz Conic, Valerio de Vita, Antonio Costanzo, Roberto Regazzini, Paolo Dm Pigatto, Nicola L Bragazzi, Alessia Pacifico, Piergiorgio Malagoli

Research output: Contribution to journalArticle


Psoriasis is a chronic, systemic inflammatory disease that in the moderate to severe forms may benefit of biologics, namely TNF and IL-12/23 and IL-17 inhibitors. Loss of response, lack of response or discontinuation due to adverse events represent a concrete therapeutic challenge for dermatologists that have to switch patients to other treatments. Although some evidences already exist toward the switch from IL-12/23 and TNF inhibitors to IL-17 inhibitors, conversely nothing is present toward the switch from IL-17 inhibitors to IL-12/23 and TNF inhibitors. We performed a real-life study enrolling 50 patients randomly switched to adalimuamb, a TNF inhibitor, or ustekinumab, an IL-12/23 inhibitor. Our observational study suggests that switching from IL-17i to TNFi and IL-12/23i is a safe and effective therapeutic strategy. This article is protected by copyright. All rights reserved.
Original languageEnglish
Pages (from-to)e12793
JournalDermatologic Therapy
Publication statusPublished - Dec 5 2018


Cite this